{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:56:49Z","timestamp":1776419809359,"version":"3.51.2"},"reference-count":24,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Chronic myelomonocytic leukaemia (CMML) is a rare overlap syndrome between myelodysplastic neoplasms and myeloproliferative neoplasms. One distinct associated condition is systemic inflammatory and autoimmune disorders (SIADs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of newly diagnosed CMML patients at our institution between January 2006 and December 2020, comparing those with and without SIADs. Clinical characteristics, laboratory findings, molecular profiles, survival outcomes and leukaemic transformation rates were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 108 patients were included, of whom 26.9% had SIADs. Immune cytopenia was the most common SIAD, with 51.7% diagnosed concurrently with CMML. Most patients (93.5%) were classified as CMML-1, and 61.1% had the myeloproliferative phenotype. The most frequent mutation was\n                      <jats:italic>TET2<\/jats:italic>\n                      (25.0%). Patients with SIADs showed a trend toward lower frequencies of\n                      <jats:italic>ASXL1<\/jats:italic>\n                      (p=0.078) and\n                      <jats:italic>NRAS<\/jats:italic>\n                      (p=0.080) mutations. The median overall survival (OS) was 14.1 months, with a 1-year survival rate of 54%. The 1-year cumulative incidence of leukaemic transformation was 19.3%, and the 1-year leukaemia-free survival (LFS) rate was 49%. Patients with SIADs showed a trend towards longer OS (32.7 vs 9.9 months; p=0.058) and a significantly better LFS (32.7 vs 8.1 months; p=0.017). After adjusting for\n                      <jats:italic>ASXL1<\/jats:italic>\n                      and\n                      <jats:italic>NRAS<\/jats:italic>\n                      mutations and haemoglobin &lt;10 g\/dL, SIADs remained protective against leukaemic transformation (HR, 0.13; p=0.038).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SIADs occur in a substantial subset of CMML patients and are associated with significantly better LFS and reduced risk of leukaemic transformation, with a trend towards improved OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>TCTR20210810003.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jcp-2025-210517","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:20:24Z","timestamp":1772648424000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of concurrent autoimmune conditions on clinical outcomes and leukaemic transformation in chronic myelomonocytic leukaemia"],"prefix":"10.1136","volume":"79","author":[{"given":"Tarinee","family":"Rungjirajittranon","sequence":"first","affiliation":[{"name":"Center of Excellence of Siriraj Adult Acute Myeloid\/Lymphoblastic Leukemia (SiAML), Siriraj Hospital, Bangkok, Thailand"},{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Ponvilawan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanya","family":"Sukpanichnant","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"},{"name":"Academy of Science, Royal Society of Thailand, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1262-2005","authenticated-orcid":false,"given":"Weerapat","family":"Owattanapanich","sequence":"additional","affiliation":[{"name":"Center of Excellence of Siriraj Adult Acute Myeloid\/Lymphoblastic Leukemia (SiAML), Siriraj Hospital, Bangkok, Thailand"},{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2026041702051369000_79.5.315.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"2026041702051369000_79.5.315.2","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2022015850"},{"key":"2026041702051369000_79.5.315.3","doi-asserted-by":"crossref","first-page":"101136","DOI":"10.1016\/j.beha.2019.101136","article-title":"Autoimmune disease in CMML-the chicken or the egg?","volume":"33","author":"Ambinder","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026041702051369000_79.5.315.4","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428194.2016.1243681","article-title":"Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia","volume":"58","author":"Zahid","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2026041702051369000_79.5.315.5","doi-asserted-by":"publisher","DOI":"10.1159\/000365877"},{"key":"2026041702051369000_79.5.315.6","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.27271","article-title":"Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management","volume":"99","author":"Patnaik","year":"2024","journal-title":"Am J Hematol"},{"key":"2026041702051369000_79.5.315.7","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res"},{"key":"2026041702051369000_79.5.315.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01140","article-title":"The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review","volume":"10","author":"Ma","year":"2019","journal-title":"Front Immunol"},{"key":"2026041702051369000_79.5.315.9","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000847","article-title":"Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders","volume":"7","author":"Dussiau","year":"2023","journal-title":"Hemasphere"},{"key":"2026041702051369000_79.5.315.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.05.013"},{"key":"2026041702051369000_79.5.315.11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272559"},{"key":"2026041702051369000_79.5.315.12","article-title":"Chronic myelomonocytic leukemia and autoimmune disorders","volume":"216357","author":"Pinto Solano","year":"2018","journal-title":"EHA Library"},{"key":"2026041702051369000_79.5.315.13","doi-asserted-by":"publisher","DOI":"10.1101\/gr.229102. Article published online before print in May 2002"},{"key":"2026041702051369000_79.5.315.14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.1.308"},{"key":"2026041702051369000_79.5.315.15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1015"},{"key":"2026041702051369000_79.5.315.16","unstructured":"WHO Classification of Tumours Editorial Board . Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer, 2024. Available: https:\/\/publications.iarc.who.int\/637"},{"key":"2026041702051369000_79.5.315.17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"key":"2026041702051369000_79.5.315.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311019"},{"key":"2026041702051369000_79.5.315.19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.751630","article-title":"Immune Phenomena in Myeloid Neoplasms: An \u201cEgg or Chicken\u201d Question","volume":"12","author":"Barcellini","year":"2021","journal-title":"Front Immunol"},{"key":"2026041702051369000_79.5.315.20","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1182\/bloodadvances.2023011050","article-title":"Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis","volume":"7","author":"Adrianzen-Herrera","year":"2023","journal-title":"Blood Adv"},{"key":"2026041702051369000_79.5.315.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev294"},{"key":"2026041702051369000_79.5.315.22","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-025-00753-2","article-title":"Contemporary CMML Risk Stratification and Management","volume":"20","author":"Sastow","year":"2025","journal-title":"Curr Hematol Malig Rep"},{"key":"2026041702051369000_79.5.315.23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-024-01087-7","article-title":"Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia","volume":"14","author":"Wang","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026041702051369000_79.5.315.24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2025-210517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:06:08Z","timestamp":1776416768000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2025-210517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,17]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jcp-2025-210517"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2025-210517","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}